News

  • Climate Protection: The gobally operating CDMO Vetter reduces the emissions of greenhouse gases to zero and no longer has a CO2 footprint.

     

    Read more
  • The CDMO headquartered in Laupheim/Germany significantly expands cGMP manufacturing capacity at its existing U.S. site in Milford.

    Read more
  • Rich R&D portfolio: In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before.

    Read more
  • New location in Austria: CDMO Vetter has further invested in additional capacity to meet this growing global demand.

    Read more
  • Contract development and manufacturing organization expands production of highly complex antibodies at German site.

    Read more
  • Quantum computing in Biopharma R&D: Boehringer Ingelheim joins the Quantum Technology and Application Consortium as a founding member.

    Read more
  • Once again, Vetter's excellence in business has been rewarded with the Axia Best Managed Companies Award.

     

     

    Read more
  • With a sales growth of 3% and the highest R&D investment in the company's history, 2020 was a good year for Boehringer Ingelheim despite impact of COVID-19.

    Read more
  • Ulm to become one of the sites of a new German Center for Child and Adolescent Health

     

    Read more
  • Vetter opens new branch office in China: The new sales office in Shanghai is the fourth office in the Asia-Pacific region.

     

    Read more
  • Vetter was granted the CMO Leadership Award 2021 in five core categories.

    Read more
  • Rentschler Biopharma establishes Center of Excellence for cell and gene therapy in the UK, and will build new ATMP capacity at the site in Stevenage.

     

    Read more
  • CureVac further strengthens its global manufacturing network: Rentschler Biopharma is responsible for manufacturing, downstream processing and formulation of CureVac's CVnCoV at its site in Laupheim.

    Read more
  • Science Magazine has named the development of effective vaccines against COVID-19 at record speed as 2020’s top scientific achievement.

    Read more
  • Well-Deserved Recognition: The Top Employers Institute awarded Boehringer Ingelheim as a one of the world’s 16 best employers.

     

    Read more
  • Boehringer Ingelheim joins forces with Google to breake new ground in the application of quantum computing in pharmaceutical research and development.

    Read more
  • In a pilot project involving the University and the University Hospital Tübingen, a start-up based in Ulm is testing the production of personalied drugs using digital 2D/3D printing.

     

    Read more
  • Boehringer Ingelheim signs the agreement on the acquisition of all shares of Labor Dr. Merk & Kollegen to strengthen its Next Generation Cancer Immunology Program.

     

    Read more
  • Boehringer Ingelheim today announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel.

    Read more
  • Vetter, a globally leading contract development and manufacturing organization (CDMO), has moved into its new headquarters in Ravensburg, Germany.

    Read more
  • Rentschler Biopharma contributes to manufacturing of COVID-19 mRNA vaccine.

    Read more
  • First half 2020: Minimizing the impact of the COVID-19 pandemic on its employees, patients and society are priorities for Boehringer Ingelheim.

     

     

    Read more
  • Vetter and Rentschler Biopharma team up to simplify processes and optimize time-to-market.

    Read more
  • Rentschler announces the signing of a commercial license agreement for the production of highly complex proteins.

     

    Read more
  • Boehringer Ingelheim Biopharmaceuticals China Ltd. has been awarded with a 2020 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE).

    Read more
  • Boehringer Ingelheim has stepped up its efforts in the fight against the COVID-19 pandemic, backed by strong business performance in previous years, including 2019.

    Read more
  • The Biotech World as Guest at the BioPharma Cluster South Germany.

    Read more
  • Ulm University: Among top 150 universities worldwide and Germany's top 15.

     

    Read more